       Document 0841
 DOCN  M95A0841
 TI    [Treatment of spastic paraparesis with botulinum toxin with reference to
       beneficial effects, disease severity and long-term treatment]
 DT    9510
 AU    Takenaga S; Kawahigashi Y; Sonoda Y; Horikiri T; Hirata K; Arimura K;
       Osame M; Third Department of Internal Medicine, Kagoshima University;
       School of Medicine.
 SO    Rinsho Shinkeigaku. 1995 Mar;35(3):251-5. Unique Identifier : AIDSLINE
       MED/95339621
 AB    We administered local botulinum toxin injections on the leg adductors of
       12 patients with spastic paraparesis (9 patients with HAM, 2 patients
       with spinal spastic paraparesis, 1 patient with an identified
       degenerative disease). Two of them were wheelchair-bound and the other
       patients could walk with or without help. The patients were assessed by
       the time to walk 10 m and the spasticity score which was derived from
       the degree of muscle tone and spasm frequency of leg adductors. After
       the initial injection, 7 of the 12 patients improved spasticity scores
       and 8 of the 10 patients could walk 10 m within a shorter time. The time
       to walk 10 m was markedly shortened in moderate cases. However, one
       patient complained of leg weakness and the time to walk 10 m was
       prolonged. Five of the 12 patients received injections 3 to 7 times, and
       were followed up for a mean of 16.2 months. In 4 of the 5 patients,
       repeated injections could maintain the improvement of spasticity score
       and time to walk 10 m. However, injection was discontinued in one
       patient because of leg weakness. The other side effects were pain and
       swelling at the injected site and dysarthria. However, these side
       effects were slight and transient and did not require treatment. No
       other systemic side effects were observed. In conclusion, the beneficial
       effects of botulinum injections to spastic paraparesis were (1)
       improvement of objective symptoms in mild cases, (2) improvement of ADL
       in moderate cases, and (3) improvement of objective symptoms and ease of
       nursing care in severe cases. Furthermore, we confirmed the long-term
       efficacy and safety of botulinum toxin.
 DE    Adult  Aged  Botulinum Toxins/*ADMINISTRATION & DOSAGE  English Abstract
       Female  Human  Injections, Intramuscular  Male  Middle Age  Paraparesis,
       Tropical Spastic/PHYSIOPATHOLOGY/*THERAPY  Walking  CLINICAL TRIAL
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

